Drugs / Clioquinol
Clioquinol
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00963495 | Aug 2009 → Sep 2013 | Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, myelodysplastic syndrome +1 | University Health Network, Toronto | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05727943 | Mar 2022 → Dec 2023 | epilepsy | KU Leuven | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01429701 | May → Jun 2012 | dermatitis | EMS | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clioquinol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00963495 ↗ |
| Known as | 4-stearylamino-phenyl-trimethylam. metilsulf. | ChEMBL registry synonym — accepted as the source's own label CHEMBL497 ↗ |
| Known as | Clioquinol component of nystaform | ChEMBL registry synonym — accepted as the source's own label CHEMBL497 ↗ |
| Known as | Iodochlorhydroxyquin | ChEMBL registry synonym — accepted as the source's own label CHEMBL497 ↗ |
| Known as | Iodochlorhydroxyquinolone | ChEMBL registry synonym — accepted as the source's own label CHEMBL497 ↗ |
| Known as | NSC-3531 | ChEMBL registry synonym — accepted as the source's own label CHEMBL497 ↗ |
| Known as | NSC-74938 | ChEMBL registry synonym — accepted as the source's own label CHEMBL497 ↗ |
| Known as | Oralcer | ChEMBL registry synonym — accepted as the source's own label CHEMBL497 ↗ |
| Known as | Vioform | ChEMBL registry synonym — accepted as the source's own label CHEMBL497 ↗ |
| Modality | Small molecule | — CHEMBL497 ↗ |
| Route | Oral | “Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy” NCT00963495 ↗ |